PND38 Cost Minimization Analysis of Fingolimod Versus Natalizumab in the Second-Line Treatment of Remittent-Recurrent Multiple Sclerosis
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1962
https://www.valueinhealthjournal.com/article/S1098-3015(12)03675-3/fulltext
Title :
PND38 Cost Minimization Analysis of Fingolimod Versus Natalizumab in the Second-Line Treatment of Remittent-Recurrent Multiple Sclerosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03675-3&doi=10.1016/j.jval.2012.08.1962
First page :
A552
Section Title :
Neurological Disorders
Open access? :
No
Section Order :
1450